New Jersey, USA-based Merck & Co (NYSE: MRK) has been granted a Priority Review from the US regulator for its pulmonary arterial hypertension (PAH) candidate sotatercept.
The decision reflects the fact that there is a high level of unmet medical need for people with PAH, a rare, progressive and life-threatening blood vessel disorder for which there are no available disease-modifying therapies.
The update comes after Merck announced positive results for the candidate, in March, with data showing the therapy significantly improved exercise capacity, the study’s primary endpoint.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze